Please use this identifier to cite or link to this item:
Title: 18F-FDG Metabolic Tumor Volume: Association with Short- and Long-Term Feeding Tube Use in Head and Neck IMRT.
Austin Authors: Jackson, James E;Anderson, Nigel J;Rolfo, Maureen;Wada, Morikatsu ;Schneider, Michal;Poulsen, Michael;Fahandej, Maziar;Huynh, Anna;Lee, Sze Ting ;Joon, Daryl Lim;Khoo, Vincent
Affiliation: Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
Faculty of Medicine, The University of Queensland, Herston, QLD, Australia
Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Department of Clinical Oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Chelsea, London, UK
Department of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Radiation Oncology Centres, Gold Coast University Hospital, 1 Hospital Boulevard, Southport, QLD, 4215, Australia
School of Medicine, Griffith University, Gold Coast, Australia
Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Australia
Department of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Department of Medical Imaging and Radiation Sciences, Monash University, Clayton, Victoria, Australia
Issue Date: 28-Sep-2018 2018-09-28
Publication information: Dysphagia 2019; 34(3): 341-349
Abstract: The purpose of this study was to investigate whether the metabolic tumor volume (MTV) of head and neck primary tumors may be a significant prognostic factor for feeding tube (FT) use and FT dependence. Seventy-nine patients with evaluable primary tumors, pre-therapy FDG-PET scans, treated with definitive intensity-modulated radiotherapy (IMRT) (± concurrent chemotherapy) for head and neck mucosal cancers were included. MTV was quantified and recorded for the primary lesion using a minimum standardized uptake value (SUV) threshold of 2.0. Patients were recommended prophylactic FT and followed up by a dietician for at least eight weeks of post-radiotherapy. Associations between MTV, dose to swallowing organs at risk, FT use, and FT dependence were analyzed. MTV was positively correlated with gross tumor volume (GTV) (r = 0.7357; p < 0.0001). MTVs larger than 17 cc were associated with higher rates of FT use (87.8% vs. 69.5%, p = 0.0067) and FT dependence at six weeks (76.7% vs. 41.7%, p = 0.0024) and six months (25.0% vs. 8.7%, p = 0.0088). Increasing MTV was associated with increasing mean dose to the oral cavity (p = < 0.0001), tongue base (p = 0.0009), and superior (SPCM) (p = 0.0001) and middle pharyngeal constrictor muscles (MPCM) (p = 0.0005). Increasing MTV was associated with increasing maximum dose to oral cavity (p = 0.0028), tongue base (p = 0.0056), SPCM (p = 0.0037), and MPCM (p = 0.0085). Pre-treatment MTV is a reproducible parameter that can be generated at or prior to a pre-treatment Multidisciplinary Tumor Board and may expedite decisions regarding placement of prophylactic FTs. Prospective evaluation in larger series is required to determine whether MTV is a more useful prognostic variable for FT use than clinical T-classification.
DOI: 10.1007/s00455-018-9946-z
ORCID: 0000-0002-4826-2339
PubMed URL: 30267142
Type: Journal Article
Subjects: Enteral nutrition
Head & neck neoplasms
Positron-emission tomography
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 29, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.